Adaptive Servo-ventilation Therapy Results in the Prevention of Arrhythmias in Patients with Heart Failure Due to Ischemic Heart Disease

• Published in: Internal Medicine 2021/11/15, Vol.60(22), pp.3551-3558
• Main Authors: Nagasaka, Takashi, Takama, Noriaki, Ohyama, Yoshiaki, Koitabashi, Norimichi, Tange, Shoichi, Kurabayashi, Masahiko
• Format: Article
• Language: English
• Subjects: adaptive servo-ventilation; Aged; Aged, 80 and over; Arrhythmia; Atrial Fibrillation; Brain natriuretic peptide; Cardiac arrhythmia; Cardiovascular disease; Cardiovascular diseases; Congestive heart failure; Coronary artery disease; Epidermal growth factor receptors; Fibrillation; Glomerular filtration rate; Heart failure; Heart Failure - complications; Heart Failure - prevention & control; Heart rate; Humans; Internal medicine; Ischemia; Male; Middle Aged; Myocardial Ischemia - complications; Myocardial Ischemia - prevention & control; Original; Patients; Population studies; Regression analysis; Renal function; Respiration, Artificial; Retrospective Studies; Risk factors; safety and efficacy; Sleep Apnea Syndromes; sleep-disordered breathing; Stroke Volume; Tachycardia; Treatment Outcome; Ventilation; Ventricle; Ventricular Function, Left
• ISSN: 0918-2918; 1349-7235
• DOI: 10.2169/internalmedicine.7439-21

Objective Whether or not adaptive servo-ventilation (ASV) is effective in preventing arrhythmias in patients with heart failure (HF) due to ischemic heart disease (IHD) is unclear. This study estimated the effects of ASV therapy on arrhythmias in patients with HF due to IHD. Methods One hundred and forty-one consecutive hospitalized patients with HF due to IHD (mean age: 74.9±11.9 years old) were retrospectively assessed in this study. Of the 141 patients, 75 were treated with ASV (ASV group), and 66 were treated without ASV (Non-ASV group). We estimated the incidence of arrhythmias, including paroxysmal atrial fibrillation (PAF) and ventricular tachycardia (VT), during one-year follow-up in both groups using multivariable logistic regression models. Results Men accounted for 55.3% of the study population. There were no significant differences in the baseline clinical characteristic data between the ASV and Non-ASV groups with respect to age, sex, heart rate, risk factors, oral medication, or laboratory data, including the estimated glomerular filtration rate (eGFR), brain natriuretic peptide, and left ventricular ejection fraction. ASV therapy was associated with a reduced incidence of arrhythmia after adjusting for demographic and cardiovascular disease risk factors (odds ratio, 0.27; 95% confidence interval, 0.11 to 0.63; p